PAPUA New Guinea is now benefiting from new, life-saving treatments for drug-resistant tuberculosis (TB), made possible through long-term investment and collaboration with Australia.
Marking World TB Day on March 24, Australia highlighted the impact of its support in transforming TB care across the region, including in Papua New Guinea, where TB remains a major public health challenge.
Australia has invested about PGK51 million (AUD17 million) to support research and development of new TB drugs, helping bring more effective treatments to market. These efforts have led to shorter, safer, and more effective treatment options for patients with drug-resistant TB.
The impact is already being seen locally, with the rollout of the new all-oral BPaLM treatment in Port Moresby and Daru.
The new regimen significantly reduces the burden on patients. Previously, those with drug-resistant TB had to take
more than 20 tablets daily for over 18 months, along with regular injections. Under the new treatment, patients take just five tablets a day for six months.
Health officials say the new drugs have cut treatment time by two-thirds and improved outcomes, with TB treatment success rates in PNG rising from 71 per cent in 2020 to 88 per cent in 2025. The new regimen also offers cure rates of more than 90 per cent.
Australia’s support has gone beyond funding. Technical partners such as the Therapeutic Goods Administration and the Burnet Institute worked closely with PNG authorities to fast-track approval and rollout of the medicines.
In addition, Australia has used its position on the board of the Global Fund to Fight AIDS, Tuberculosis and Malaria to help prioritize access to these treatments across the region.
The rollout of the new TB drugs highlights the importance of sustained investment, scientific innovation, and strong partnerships in tackling one of the world’s deadliest infectious diseases.
Australia reaffirmed its commitment to continue working alongside Papua New Guinea to strengthen TB care, improve treatment outcomes, and protect communities, with the shared goal of ending TB.